SCHEMBL1014939

SCHEMBL1014939

COC(C)(NC(=O)O)c1ccccc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNN4 O15554 2/20 0.40
▸ CNR2 P34972 1/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ ALDH1A1 P00352 4/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ GLA P06280 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ LMNA P02545 2/20 0.38
▸ HTR2A P28223 1/20 0.37
▸ HTR2C P28335 1/20 0.37
▸ ADRA1A P35348 1/20 0.37
▸ OPRK1 P41145 1/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ KIF11 P52732 1/20 0.37
▸ CES1 P23141 1/20 0.37
▸ HTT P42858 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3650057 0.83 KCNN4 (0.42) KCNN4ALDH1A1NPSR1NPC1RAB9A
SCHEMBL3649128 0.82 TSHR (0.46) KCNN4ALDH1A1NPSR1LMNAKIF11
SCHEMBL1014934 0.81 KCNN4 (0.45) KCNN4ALDH1A1NPSR1NPC1RAB9A
SCHEMBL5027223 0.80 PDK1 (0.41) KCNN4L3MBTL1ALDH1A1NPC1GLA
SCHEMBL719027 0.75 KMT2A (0.42) KCNN4L3MBTL1ALDH1A1NPC1GLA
SCHEMBL3644866 0.75 KCNN4 (0.36) KCNN4ALDH1A1NPSR1RAB9ACES1
SCHEMBL27992409 0.75 HTT (0.36) ALDH1A1NPC1RAB9AHTR2AHTR2C
SCHEMBL3447426 0.74 PDE2A (0.43) ALDH1A1LMNAHTR2AHTR2CADRA1A
SCHEMBL30966610 0.73 PLCG1 (0.49) KCNN4CNR2L3MBTL1ALDH1A1NPSR1
SCHEMBL3822998 0.73 PLCG1 (0.49) KCNN4CNR2L3MBTL1ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580823-B2 Piperidine renin inhibitors VITAE PHARMACEUTICALS, INC. (US) 2013-11-12 — — US disclosed
US-8487108-B2 Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2013-07-16 — — US disclosed
US-20120225906-A1 PIPERIDINE RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2012-09-06 — — US disclosed
US-8198453-B2 Piperidine renin inhibitors VITAE PHARMACEUTICALS, INC. (US) 2012-06-12 — — US disclosed
US-7872028-B2 Diaminopropanol renin inhibitors VITAE PHARMACEUTICALS, INC. (US) 2011-01-18 — — US disclosed
US-20100048636-A1 Aspartic Protease Inhibitors VITAE PHARMACEUTICALS, INC. 2010-02-25 — — US disclosed
US-20090312369-A1 Renin Inhibitors VITAE PHARMACEUTICALS , INC. 2009-12-17 — — US disclosed
US-20090186884-A1 such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders VITAE PHARMACEUTICALS, INC. 2009-07-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048636-A1 Aspartic Protease Inhibitors DNPEP, PEPD, SERPINB1 KCNN4 4371/4885CNR2 4640/4885L3MBTL1 3699/4885
US-20120225906-A1 PIPERIDINE RENIN INHIBITORS ACE, PEPD, DNPEP KCNN4 2148/4885CNR2 4077/4885L3MBTL1 4830/4885
US-20090186884-A1 such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders DNPEP, ACE, DPEP1 KCNN4 3426/4885CNR2 2405/4885L3MBTL1 1464/4885
US-20090312369-A1 Renin Inhibitors ACE, REN, DNPEP KCNN4 3106/4885CNR2 4534/4885L3MBTL1 4521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback